个人中心 - 老虎社区

AK1208

IP属地：未知

帖子 · 11帖子 · 11
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- AK1208AK1208
  ·2021-06-24
  Interesting
  非常抱歉，此主贴已删除
  1,091 1
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-24
  Cool
  非常抱歉，此主贴已删除
  793 1
  5
  分享
  举报
- AK1208AK1208
  ·2021-06-23
  Cool
  非常抱歉，此主贴已删除
  979 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-23
  Wow
  非常抱歉，此主贴已删除
  1,028 评论
  点赞
  分享
  举报
- AK1208AK1208
  ·2021-06-22
  Wow
  非常抱歉，此主贴已删除
  786 1
  3
  分享
  举报
- AK1208AK1208
  ·2021-06-22
  Cool
  非常抱歉，此主贴已删除
  1,049 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-21
  Wow
  非常抱歉，此主贴已删除
  1,020 1
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-20
  Noted
  非常抱歉，此主贴已删除
  1,028 评论
  1
  分享
  举报
- AK1208AK1208
  ·2021-06-19
  Wow
  非常抱歉，此主贴已删除
  1,190 评论
  2
  分享
  举报
- AK1208AK1208
  ·2021-06-18
  Awesome
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress
  Shares of Clearside Biomedical(CLSD) jumped on Thursday after analysts at Wedbush tripled their pri
  Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress
  1,197 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582542713091138","uuid":"3582542713091138","gmtCreate":1619491143389,"gmtModify":1619491143389,"name":"AK1208","pinyin":"ak1208","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.25","exceedPercentage":"80.08%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":126143058,"gmtCreate":1624548770474,"gmtModify":1634004491816,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126143058","repostId":"1120836318","repostType":4,"isVote":1,"tweetType":1,"viewCount":1091,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126140402,"gmtCreate":1624548717406,"gmtModify":1634004492511,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Cool&nbsp;","listText":"Cool&nbsp;","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/126140402","repostId":"1162964404","repostType":4,"isVote":1,"tweetType":1,"viewCount":793,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129499299,"gmtCreate":1624379715411,"gmtModify":1634006949785,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129499299","repostId":"1118580429","repostType":4,"isVote":1,"tweetType":1,"viewCount":979,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129400702,"gmtCreate":1624379359706,"gmtModify":1634006956522,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129400702","repostId":"1118580429","repostType":4,"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120926014,"gmtCreate":1624292738838,"gmtModify":1634008229069,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/120926014","repostId":"2145084835","repostType":4,"isVote":1,"tweetType":1,"viewCount":786,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":120929331,"gmtCreate":1624292558223,"gmtModify":1634008231903,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/120929331","repostId":"1186997776","repostType":4,"isVote":1,"tweetType":1,"viewCount":1049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164220477,"gmtCreate":1624209701799,"gmtModify":1634009449434,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/164220477","repostId":"2144218770","repostType":4,"isVote":1,"tweetType":1,"viewCount":1020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165543938,"gmtCreate":1624153212724,"gmtModify":1634010252883,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Noted&nbsp;","listText":"Noted&nbsp;","text":"Noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165543938","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":1028,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162557987,"gmtCreate":1624069075849,"gmtModify":1634011142852,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162557987","repostId":"2144771068","repostType":4,"isVote":1,"tweetType":1,"viewCount":1190,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168986782,"gmtCreate":1623946848746,"gmtModify":1634025396950,"author":{"id":"3582542713091138","authorId":"3582542713091138","name":"AK1208","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3582542713091138","authorIdStr":"3582542713091138"},"themes":[],"htmlText":"Awesome","listText":"Awesome","text":"Awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168986782","repostId":"1179547045","repostType":4,"repost":{"id":"1179547045","kind":"news","pubTimestamp":1623941450,"share":"https://www.laohu8.com/m/news/1179547045?lang=&edition=full","pubTime":"2021-06-17 22:50","market":"us","language":"en","title":"Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1179547045","media":"thestreet","summary":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their pri","content":"<p>Shares of Clearside Biomedical(<b>CLSD</b>) &nbsp;jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.</p>\n<p>Wedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.</p>\n<p>\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.</p>\n<p>Shares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.</p>\n<p>Clearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.</p>\n<p>Earlier this week the company&nbsp;reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.</p>\n<p>Clearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.</p>\n<p>The company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.</p>\n<p>Earlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClearside Jumps; Wedbush Triples Target After Eye-Drug Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush ...</p>\n\n<a href=\"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLSD":"Clearside Biomedical Inc."},"source_url":"https://www.thestreet.com/investing/clearside-biomedical-stock-jumps-on-wedbush-upgrade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1179547045","content_text":"Shares of Clearside Biomedical(CLSD)  jumped on Thursday after analysts at Wedbush tripled their price target for the company following positive data from the early stage eye treatment study.\nWedbush analyst Liana Moussatos rates the stock outperform and tripled her price target to $18 a share.\n\"We find these initial results encouraging by first establishing a clear foundation of safety,\" Moussatos said.\nShares of Clearside Biomedical at last check jumped 36% to $5.53. The shares on Thursday have traded at a 52-week high $5.66, up 39%. And they've bounced off a 52-week low $1.25, touched at the end of October.\nClearside shares have been volatile, falling as low as $2.24 per share in late March. But since the calendar flipped to June, the stock as jumped more than 50%, including Thursday's jump.\nEarlier this week the company reported progress in a clinical trial of CLS-AX, a drug for pretreated wet age-related macular degeneration.\nClearside said the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed throughout the study.\nThe company said the improvements were reflected in the BCVA score, or best corrected visual acuity, with five of six patients each gaining four or more letters.\nEarlier this week the results prompted an analyst to call the treatment \"a game changer.\" Roth Capital analyst Zegbeh Jallah reiterated a buy rating and $9 price target on Clearside after the company reported data from the study.","news_type":1,"symbols_score_info":{"CLSD":0.9}},"isVote":1,"tweetType":1,"viewCount":1197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}